In vitro, the inhibitor sensitized subsets of HPV-negative and HPV-positive HNSCC cell lines to TNF family death ligands TNFα and TRAIL, which involved a reactivation of p53 in the HPV-positive strains. Here, TP53 is linked to head and neck squamous cell carcinoma.